Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.

Original publication

DOI

10.1016/j.eururo.2016.07.015

Type

Journal article

Journal

European urology

Publication Date

12/2016

Volume

70

Pages

906 - 908

Addresses

Department of Oncology/Haematology, Kantonsspital, St. Gallen, Switzerland.

Keywords

STAMPEDE Trial Management Group, Humans, Prostatic Neoplasms, Neoplasm Metastasis, Hyperglycemia, Metformin, Androgen Antagonists, Hypoglycemic Agents, Drug Therapy, Combination, Orchiectomy, Male, Drug Repositioning